MÉDICAMENT DE COMBINAISON COMPRENANT IL-12 ET UN AGENT DE BLOCAGE DE MOLÉCULES INHIBITRICES DES LYMPHOCYTES T POUR LA THÉRAPIE DE TUMEURS

• 收藏
• 分享

专利权人:

Universität Zürich

发明人:

申请号：

EP18160057.8

公开号：

EP3351261A1

申请日:

2012.10.10

申请国别(地区):

EP

年份:

2018

代理人:

摘要：

The invention relates to a combination medicament for use in the therapy of a malignant neoplastic disease, comprising an IL-12 polypeptide, or a nucleic acid expression vector encoding said IL-12 polypeptide, and a non-agonist ligand, particularly an antibody, capable of binding to one of PD-1, PD-L1 or PD-L2, with a dissociation constant of at least 10-7 M-1. The non-agonist ligand is provided as a dosage form for systemic delivery, and the IL-12 polypeptide, or said nucleic acid expression vector, is provided by administration into a tumour, into the vicinity of a tumour, or to the lymph node associated with a tumour.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/